Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.

Products

We are an integrated biotechnology company dedicated to rare diseases. Our research and product portfolio is primarily focused on haemophilia, inflammation and genetic and metabolic diseases.
Products

Transparency

Sobi supports transparency initiatives, including the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code in Europe and the Physician Payments Sunshine Act in the United States (Sunshine Act).
Read more

Annual General Meeting 2018

The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, will be held on Wednesday, 9 May, 2018 at 3.00 p.m. at Näringslivets Hus, Storgatan 19, Stockholm, Sweden.
Read more

Share Price

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne